Congenital pulmonary airway malformation type 2

Summary

Congenital pulmonary airway malformation type 2 (MONDO:0017250) is a disease. A subtype of congenital pulmonary airway malformation — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	congenital pulmonary airway malformation type 2
Mondo ID	MONDO:0017250
Orphanet	280840
ICD-11	1921224131
UMLS	C5437761
MedGen	1738105
GARD	0021095
Is cancer (heuristic)	no

Also known as: CCAM type 2 · congenital cystic adenomatoid malformation of the lung type 2 · congenital cystic adenomatous malformation of the lung type 2 · congenital cystic disease of the lung type 2 · CPAM type 2

Disease family

This is a subtype of congenital pulmonary airway malformation. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › congenital pulmonary airway malformation › congenital pulmonary airway malformation type 2

Related subtypes (4): congenital pulmonary airway malformation type 0, congenital pulmonary airway malformation type 1, congenital pulmonary airway malformation type 3, congenital pulmonary airway malformation type 4

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.